Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vectura Heads To Auction As Carlyle And Philip Morris Raise Stakes

Both Parties Submitted Increased Proposals For UK Respiratory Firm

Executive Summary

Private equity group Carlyle and tobacco giant Philip Morris International are caught in a tug-of-war for UK-based respiratory specialist Vectura, after submitting revised bids for the company.

You may also be interested in...



Vectura Opts For Tobacco Giant Philip Morris In Carlyle Takeover Tussle

Vectura’s board of directors has chosen cigarette manufacturer Philip Morris’ superior cash offer, turning down US private equity Carlyle, following a months-long battle between the two bidders for the inhalation specialist that was set to go to a rare auction in the UK.

Hikma Raises Expectations For 2021 After A Host Of Launches

On the back of a string of launches in 2021 – including the full introduction to the US market of its generic rival to Advair – Hikma has raised its full-year forecast for its generics business in anticipation of a healthy second half.

Vectura Agrees £958m Takeover Following Hikma Advair Launch

Weeks after partner Hikma launched its generic version of GSK’s Advair, Wiltshire-based Vectura has agreed a takeover offer by private equity Carlyle, which aims to build a market leading inhalation specialist CDMO.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel